** Shares of medical device maker Dexcom DXCM.O fall 6.2% to $73 in extended trade

** Co says it had received a warning letter from the U.S. FDA following inspections of its two key manufacturing facilities

** The warning letter contains observations and identified issues in manufacturing processes and quality management system at DXCM's facilities in San Diego, California and Mesa, Arizona

** Co does not expect a material impact from the letter to its manufacturing capacity or its sales outlook for fiscal year 2025

** DXCM fell 37.3% in 2024

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))